Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by coyote13on Mar 23, 2017 9:00am
290 Views
Post# 26018982

RE:RE:PROMETIC TO REPORT ITS FOURTH QUARTER AND YEAR-END 2016 FINA

RE:RE:PROMETIC TO REPORT ITS FOURTH QUARTER AND YEAR-END 2016 FINAScott, I would not get your hopes up.

PL has reverted to his prior practices of promising more than he appears able to deliver. He needs to be coached to say less while emphacizing that the company is sticking to its plan.

I think a financing will come prior to the AGM. PLI have been serial issuers in the springtime and I expect 2017 to be no different. The news will be softened with the " allows PLI to retain more of the economics of the product". Of course, we don't know what ownership economics were assumed in PLI's financing  outlook  anyway. I am growing weary of this form of excuse.

As for a partnership, I am comforted by the fact the Board of Directors created an Asset Monetization Committee to monitor management plans in that regard. I recall from the 2016 Proxy Circular that this Committee met atleast twice in fiscal 2015. It will be interesting to see how active the Committee was in 2016.

The RBC report update comes at a curious time. Why not wait for Q4 numbers seeing as it is only a week away  and incorporate managements " official "posturing on Plasminogen approval and related rollout. What does RBC know. What PLI has overlooked, in their approach to public market communication, is having set the street up for mid year timing and " missed", there ought to be a series of " downgrades" by all analysts. Yes its only "delayed by a quarter" but PLI when they issue timelines should " under promise and over deliver". Does not look good if PL is trying to bring more institutional following on board.

I do agree however that 2017 must be a year of execution.

GLTA

Coyote13
Bullboard Posts